|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
List of Ongoing Clinical Trials: Patient Summary
SWOG S0434
Phase II Study of Sorafenib in Patients with Relapsed or Refractory Multiple
Myeloma
Summary
Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
This phase II trial is studying how well sorafenib works in treating patients with relapsed or refractory multiple myeloma.
Consent Form for Patients | Fast Fact Sheet